Immuneel Secures Latest Funding Round

Immuneel secured an undisclosed amount in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Immuneel Raises an undisclosed amount in Funding

Immuneel is a Bengaluru-based Digital Health company focused on scale CAR-T therapies.

Investors Behind the Funding

The round was backed by a mix of new, </strong>, Singularity AMC, Rainmatter by Zerodha</strong> · The round also saw participation from, including founder Kiran Mazumdar-Shaw, Eight Roads Ventures. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Immuneel operates in Healthcare & Life Sciences. Immuneel's Series B round shows investors are still backing digital health platforms with real scale narratives. At fresh capital, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

scale CAR-T therapies

Looking Ahead

Immuneel raises ₹100 cr in Series B round to scale CAR-T therapies

Source reference: original announcement/article.